Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Genetic Variation in CES1 on Antiplatelet Therapy
NCT03161678Phase 4Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Aug 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of clopidogrel and ticagrelor in myocardial infarction (MI) and thrombosis (3 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Change in Maximal Platelet Aggregation in Response to Clopidogrel at 8 days and Change in Maximal Platelet Aggregation in Response to Ticagrelor at 8 days. Started Aug 2017; status: completed.
02
Drugs
clopidogrelticagrelor
03
Conditions
myocardial infarction (MI)thrombosis
Beyond the preview
Go deeper on NCT03161678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161678.